5 assets in Adult Hepatocellular Carcinoma

Therapeutic assets addressing Adult Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cobolimab Adult Hepatocellular Carcinoma	University of Hawaii	P2	CCC (53)
Dostarlimab Adult Hepatocellular Carcinoma	University of Hawaii	P2	CCC (53)
Cabozantinib Adult Hepatocellular Carcinoma	University of Michigan Rogel Cancer Center	P1/2	CCC (48)
ACETIC Adult Hepatocellular Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Fludeoxyglucose Adult Hepatocellular Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)